New radiation method HYDRA tested for laryngeal cancer

NCT ID NCT03114462

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new type of radiation called HYDRA for people with laryngeal cancer. The goal is to find the highest safe dose and see how well it controls the tumor. Eleven participants will receive different doses of radiation and complete quality-of-life surveys over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Stereotactic hypofractionated radioablation (HYDRA radiation)
What this could lead to
If successful, this could lead to a more effective radiation treatment for laryngeal cancer that may improve tumor control while limiting side effects.
What could go wrong
This is a very early phase 1 trial with only 11 participants, so results may not apply to all patients. The main goal is safety and dosing, not yet proving effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS OF RESPIRATORY AND INTRATHORACIC ORGANS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.